Citation: Li Xia, Yujun Song, Lan Xiao, Fan Tong, Miao Yu, Huile Gao, Ran Ran. The progress and perspective of tumor immunotherapy[J]. Chinese Chemical Letters, ;2026, 37(12): 113390. doi: 10.1016/j.cclet.2026.113390 shu

The progress and perspective of tumor immunotherapy

Li Xia ^{a, 1} ,
Yujun Song ^{b, 1} ,
Lan Xiao ^{b, 1} ,
Fan Tong ^b ,
Miao Yu ^a ,
Huile Gao ^{b, *,} ,
Ran Ran ^{a, *,}

a.
Department of Breast, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu 610041, China
b.
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China

gaohuile@scu.edu.cn

2548934165@qq.com

Received Date: 20 June 2026
Revised Date: 3 September 2026
Accepted Date: 4 September 2026
Available Online: 4 September 2026

Figures(7)

Immunotherapy has been the most attractive and promising strategy to conquer tumors. However, tumor immunotherapy faces many challenges, such as the immunosuppressive tumor microenvironment (TME), poor T cell infiltration, and low immune response. Recently, numerous studies have been published to overcome these barriers, and many emerging immunotherapies have been developed. In this review, we first analyze the key barriers that compromise tumor immunotherapy, focusing on the immunosuppressive TME. Next, we summarize strategies to overcome these barriers, including inducing immunogenic cell death, promoting antigen presentation, improving T cell infiltration, and blocking immune checkpoints. We then highlight emerging new strategies for tumor immunotherapy, such as regulating tumor immune microenvironment network, engineering cell therapies, utilizing microbial-based therapies, and applying targeted protein degradation. The aforementioned innovative therapeutic strategies are expected to propel tumor immunotherapy into a completely new phase of development.
- Tumor immunotherapy,
- Tumor microenvironment,
- Immunogenic cell death,
- Engineered therapy,
- Targeted protein degradation
1. [1]
  H. Sung, A.M. Filho, M. Laversanne, et al., CA Cancer J. Clin. 76 (2026) e70090.
2. [2]
  R.L. Siegel, T.B. Kratzer, A.N. Giaquinto, et al., CA Cancer J. Clin. 75 (2025) 10–45. doi: 10.3322/caac.21871
3. [3]
  A. Al-Khinji, N. Al-Korbi, S. Al-Kuwari, et al., Front. Oncol. 15 (2025) 1569884. doi: 10.3389/fonc.2025.1569884
4. [4]
  P. Dasgupta, H. Lin, G. Kumar, et al., J. Neurooncol. 175 (2025) 453–461. doi: 10.1007/s11060-025-05131-9
5. [5]
  S. Grabska, H. Grabski, T. Makunts, et al., Cancers 16 (2024) 2820. doi: 10.3390/cancers16162820
6. [6]
  J. Hu, X. Yuan, F. Wang, et al., Chin. Chem. Lett. 32 (2021) 1341–1347. doi: 10.1016/j.cclet.2020.11.006
7. [7]
  D.D. Shah, M.R. Chorawala, N.R. Raghani, et al., Med. Oncol. 42 (2025) 117. doi: 10.1007/s12032-025-02641-4
8. [8]
  E. Boedtkjer, S.F. Pedersen, Annu. Rev. Physiol. 82 (2020) 103–126. doi: 10.1146/annurev-physiol-021119-034627
9. [9]
  K. Li, H. Shi, B. Zhang, et al., Signal Transduct. Target. Ther. 6 (2021) 362. doi: 10.1038/s41392-021-00670-9
10. [10]
  J. Lu, Y. Luo, D. Rao, et al., Exp. Hematol. Oncol. 13 (2024) 39. doi: 10.1186/s40164-024-00505-7
11. [11]
  S. He, L. Zheng, C. Qi, Mol. Cancer 24 (2025) 5. doi: 10.1109/cisat66811.2025.11181725
12. [12]
  N. Sobhani, D.R. Tardiel-Cyril, A. Davtyan, et al., Cancers 13 (2021) 1440. doi: 10.3390/cancers13061440
13. [13]
  O. Goldmann, O.V. Nwofor, Q. Chen, et al., Front. Immunol. 15 (2024) 1328193. doi: 10.3389/fimmu.2024.1328193
14. [14]
  Y. Shao, W.Y. Yang, G. Nanayakkara, et al., Int. J. Drug Discov. Pharm. 3 (2024) 100022.
15. [15]
  J.T. Schnell, R.L. Briviesca, T. Kim, et al., Nat. Rev. Rheumatol. 21 (2025) 9–21. doi: 10.1038/s41584-024-01190-w
16. [16]
  Q. Yang, N. Guo, Y. Zhou, et al., Acta Pharm. Sin. B 10 (2020) 2156–2170. doi: 10.1016/j.apsb.2020.04.004
17. [17]
  Y. Li, L. Wang, W. Ma, et al., J. Transl. Med. 23 (2025) 697. doi: 10.1002/cjce.25399
18. [18]
  J. Xiao, Z. Yang, S. Wang, et al., Sci. Rep. 14 (2024) 14343. doi: 10.1038/s41598-024-65435-0
19. [19]
  J.S. Pawar, M.A. Salam, M.S.U. Dipto, et al., Cancers 17 (2025) 2484. doi: 10.3390/cancers17152484
20. [20]
  M.Y. Lee, J.W. Jeon, C. Sievers, et al., J. Immunother. Cancer 8 (2020) e001111. doi: 10.1136/jitc-2020-001111
21. [21]
  N. Pishesha, T.J. Harmand, H.L. Ploegh, Nat. Rev. Immunol. 22 (2022) 751–764. doi: 10.1038/s41577-022-00707-2
22. [22]
  S. Jhunjhunwala, C. Hammer, L. Delamarre, Nat. Rev. Cancer 21 (2021) 298–312. doi: 10.1038/s41568-021-00339-z
23. [23]
  J.M. Romero, P. Jiménez, T. Cabrera, et al., Int. J. Cancer 113 (2005) 605–610. doi: 10.1002/ijc.20499
24. [24]
  Y.T. Liu, Z.J. Sun, Theranostics 11 (2021) 5365–5386. doi: 10.7150/thno.58390
25. [25]
  J. Galon, D. Bruni, Nat. Rev. Drug Discov. 18 (2019) 197–218. doi: 10.1038/s41573-018-0007-y
26. [26]
  K. Mortezaee, Clin. Exp. Med. 24 (2024) 15. doi: 10.1007/s10238-023-01274-z
27. [27]
  F. Bayerl, P. Meiser, S. Donakonda, et al., Immunity 56 (2023) 1341–1358.e11 e11. doi: 10.1016/j.immuni.2023.05.011
28. [28]
  P. Bonaventura, T. Shekarian, V. Alcazer, et al., Front. Immunol. 10 (2019) 168. doi: 10.3389/fimmu.2019.00168
29. [29]
  K.P. Burke, A. Chaudhri, G.J. Freeman, et al., Immunity 57 (2024) 223–244. doi: 10.1016/j.immuni.2024.01.013
30. [30]
  S. Singh, D. Dey, D. Barik, et al., Signal Transduct. Target. Ther. 10 (2025) 213. doi: 10.1007/978-981-96-5281-5_19
31. [31]
  P. Azimnasab-Sorkhabi, M. Soltani-Asl, T.T. Yoshinaga, et al., Immunol. Res. 71 (2023) 679–686. doi: 10.1007/s12026-023-09378-0
32. [32]
  J. Wang, T. Yang, J. Xu, Adv. Exp. Med. Biol. 1248 (2020) 619–649. doi: 10.1007/978-981-15-3266-5_23
33. [33]
  F.K. Dermani, P. Samadi, G. Rahmani, et al., J. Cell. Physiol. 234 (2019) 1313–1325. doi: 10.1002/jcp.27172
34. [34]
  L. Huang, H. Zhu, Y. Shi, J. Hematol. Oncol. 18 (2025) 107.
35. [35]
  J. Wang, Q. Chen, T. Liang, et al., Cancer Lett. 617 (2025) 217616. doi: 10.1016/j.canlet.2025.217616
36. [36]
  A.O. Elzoghby, O. Samir, H.E. Emam, et al., Acta Pharm. Sin. B 14 (2024) 2475–2504. doi: 10.1016/j.apsb.2024.03.022
37. [37]
  G. Kroemer, L. Galluzzi, O. Kepp, et al., Annu. Rev. Immunol. 31 (2013) 51–72. doi: 10.1146/annurev-immunol-032712-100008
38. [38]
  M.L. Lotsberg, K. Wnuk-Lipinska, S. Terry, et al., J. Thorac. Oncol. 15 (2020) 973–999. doi: 10.1016/j.jtho.2020.01.015
39. [39]
  J. Zhou, G. Wang, Y. Chen, et al., J. Cell. Mol. Med. 23 (2019) 4854–4865. doi: 10.1111/jcmm.14356
40. [40]
  A. Serrano-del Valle, A. Anel, J. Naval, et al., Front. Cell Dev. Biol. 7 (2019) 50. doi: 10.3389/fcell.2019.00050
41. [41]
  Q. Wang, X. Ju, J. Wang, et al., Cancer Lett. 438 (2018) 17–23. doi: 10.1016/j.canlet.2018.08.028
42. [42]
  H. Zhao, S. Dai, Front. Pharmacol. 17 (2026) 1732407. doi: 10.3389/fphar.2026.1732407
43. [43]
  X. Zhao, K. Yang, R. Zhao, et al., Biomaterials 102 (2016) 187–197. doi: 10.1016/j.biomaterials.2016.06.032
44. [44]
  Z. Huang, Y. Chen, J. Zhang, et al., ACS Appl. Mater. Interfaces 13 (2021) 39934–39948. doi: 10.1021/acsami.1c11327
45. [45]
  F. Shen, L. Feng, Y. Zhu, et al., Biomaterials 255 (2020) 120190. doi: 10.1016/j.biomaterials.2020.120190
46. [46]
  L. Jia, Y. Hong, X. He, et al., Chin. Chem. Lett. 36 (2025) 109957. doi: 10.1016/j.cclet.2024.109957
47. [47]
  X. Duan, C. Chan, W. Lin, Angew. Chem. Int. Ed. 58 (2019) 670–680. doi: 10.1002/anie.201804882
48. [48]
  X. Sun, J. Sun, J. Lv, et al., J. Mater. Chem. B 7 (2019) 5797–5807. doi: 10.1039/c9tb01346f
49. [49]
  R. Liu, Y. An, W. Jia, et al., J. Control. Release 321 (2020) 589–601. doi: 10.1016/j.jconrel.2020.02.043
50. [50]
  W. Jia, R. Liu, Y. Wang, et al., Acta Pharm. Sin. B 12 (2022) 3354–3366. doi: 10.1016/j.apsb.2022.03.010
51. [51]
  D. Allen, M.J. Szoo, T.D. van Bergen, et al., Antib. Ther. 8 (2025) 68–85. doi: 10.1093/abt/tbaf001
52. [52]
  H. Kobayashi, P.L. Choyke, Acc. Chem. Res. 52 (2019) 2332–2339. doi: 10.1021/acs.accounts.9b00273
53. [53]
  K. Nakajima, H. Takakura, Y. Shimizu, et al., Cancer Sci. 109 (2018) 2889–2896. doi: 10.1111/cas.13713
54. [54]
  A. Nanajian, M. Scott, N.I. Burcus, et al., Vaccines 12 (2024) 633. doi: 10.3390/vaccines12060633
55. [55]
  F.R. Riyas Mohamed, S. Aldubaisi, A. Akbar, et al., Cancers 17 (2025) 2953. doi: 10.3390/cancers17182953
56. [56]
  T.J. Lai, L. Sun, K. Li, et al., Cancer Res. Commun. 4 (2024) 1834–1849. doi: 10.1158/2767-9764.crc-23-0566
57. [57]
  F.R. Riyas Mohamed, A. Yaqinuddin, Med. Oncol. 42 (2025) 213. doi: 10.1007/s12032-025-02760-y
58. [58]
  Y. Zhang, P. Naderi Yeganeh, H. Zhang, et al., Nat. Immunol. 25 (2024) 1858–1870. doi: 10.1038/s41590-024-01932-8
59. [59]
  B. Moran, M. Davern, J.V. Reynolds, et al., Cancer Lett. 559 (2023) 216121. doi: 10.1016/j.canlet.2023.216121
60. [60]
  W. Dong, B. He, Y. Cao, et al., Cell. Oncol. 48 (2025) 249–264. doi: 10.1007/s13402-024-00989-9
61. [61]
  W. Huang, Q. Zhu, Z. Shi, et al., Cell Death Discov. 10 (2024) 143. doi: 10.1002/9781119719830.ch6
62. [62]
  A. Apavaloaei, M.P. Hardy, P. Thibault, et al., Cancers 12 (2020) 2607. doi: 10.3390/cancers12092607
63. [63]
  T. Jiang, T. Shi, H. Zhang, et al., J. Hematol. Oncol. 12 (2019) 93. doi: 10.1186/s13045-019-0787-5
64. [64]
  P. Xu, H. Luo, Y. Kong, et al., Biomed. Pharmacother. 131 (2020) 110640. doi: 10.1016/j.biopha.2020.110640
65. [65]
  S.N. Khattak, K.P. Adzavon, W. Zhao, et al., Chin. Chem. Lett. 37 (2026) 112244. doi: 10.1016/j.cclet.2025.112244
66. [66]
  C. Tonini, A. Bianchi, M. Esposito, et al., J. Immunother. Cancer 14 (2026) e013812. doi: 10.1136/jitc-2025-013812
67. [67]
  L. Maso, S.A. Mosure, S.A. Rodriguez-Aponte, et al., Nat. Commun. 16 (2025) 11264. doi: 10.1038/s41467-025-66132-w
68. [68]
  X. Li, R. Cheng, D. Junyi, et al., Biomaterials 327 (2026) 123735. doi: 10.1016/j.biomaterials.2025.123735
69. [69]
  S. You, S. Li, L. Zeng, et al., Cancer Cell 42 (2024) 1415–1433.e12. doi: 10.1016/j.ccell.2024.06.014
70. [70]
  Y. Huang, M. Su, W. Lin, et al., Theranostics 15 (2025) 7677–7692. doi: 10.7150/thno.114347
71. [71]
  Y. Li, F. Tong, Y. Wang, et al., Acta Pharm. Sin. B 14 (2024) 4102–4117. doi: 10.1016/j.apsb.2024.06.003
72. [72]
  Q. Ren, X. Zhao, L. Zhou, et al., Nat. Biomed. Eng. (2026), doi:10.1038/s41551-026-01672-0. doi: 10.1038/s41551-026-01672-0
73. [73]
  M. Sadeghzadeh, S. Bornehdeli, H. Mohahammadrezakhani, et al., Life Sci. 254 (2020) 117580. doi: 10.1016/j.lfs.2020.117580
74. [74]
  B. Zhang, L. Zhao, H. Li, et al., Front. Immunol. 17 (2026) 1744671. doi: 10.3389/fimmu.2026.1744671
75. [75]
  Y. Yao, Y. Luo, Z. Wang, et al., J. Immunother. Cancer 13 (2025) e012710. doi: 10.1136/jitc-2025-012710
76. [76]
  H. Wang, W. Zhang, C. Huang, et al., Chin. Chem. Lett. 36 (2025) 111092. doi: 10.1016/j.cclet.2025.111092
77. [77]
  X. Shen, S. Fan, J. He, et al., Adv. Sci. 13 (2026) e12139. doi: 10.1002/advs.202512139
78. [78]
  W. Qian, J. Ye, S. Xia, Front. Mol. Biosci. 11 (2024) 1391046. doi: 10.3389/fmolb.2024.1391046
79. [79]
  W. Hu, J. Xu, M. Lv, et al., Nano Today 66 (2026) 102931. doi: 10.1016/j.nantod.2025.102931
80. [80]
  L. Peng, Y. Kong, J. Yan, et al., Adv. Funct. Mater. 36 (2026) e77396. doi: 10.1002/adfm.77396
81. [81]
  Y. Liu, H. Li, H. Zhao, et al., Adv. Healthc. Mater. 11 (2022) 2102781. doi: 10.1002/adhm.202102781
82. [82]
  M. Belabed, M.D. Park, C.M. Blouin, et al., Nat. Immunol. 26 (2025) 188–199. doi: 10.1038/s41590-024-02065-8
83. [83]
  M.A. Nour, M. Rajabivahid, M.S.S. Mehdi, et al., Cancer Cell Int. 25 (2025) 149. doi: 10.1186/s12935-025-03781-3
84. [84]
  Z. Wang, M. Wu, Y. Jiang, et al., J. Control. Release 380 (2025) 362–374. doi: 10.3390/electronics14020362
85. [85]
  D. Kim, N. Gong, M.G. Alameh, et al., Nat. Mater. (2026), doi:10.1038/S41563-026-02512-X. doi: 10.1038/S41563-026-02512-X
86. [86]
  G. Abril-Rodriguez, D.Y. Torrejon, W. Liu, et al., Nat. Cancer 1 (2019) 46–58. doi: 10.1038/s43018-019-0003-0
87. [87]
  R.H. Andtbacka, Y. Wang, R.H. Pierce, et al., Cancer Res. Commun. 2 (2022) 904–913. doi: 10.1158/2767-9764.crc-22-0090
88. [88]
  K. Mortezaee, Life Sci. 249 (2020) 117534. doi: 10.1016/j.lfs.2020.117534
89. [89]
  M. Wang, Y. Zhao, M. Lu, et al., J. Control. Release 395 (2026) 114982. doi: 10.1016/j.jconrel.2026.114982
90. [90]
  Y. Xie, I. Ho, Z. Liu, et al., Front. Immunol. 17 (2026) 1760044. doi: 10.3389/fimmu.2026.1760044
91. [91]
  J. Wang, Q. Zhang, Y. Li, et al., Chin. Chem. Lett. 35 (2024) 108746. doi: 10.1016/j.cclet.2023.108746
92. [92]
  J. Hu, H. Singh, Y. Jin, et al., Proc. Natl. Acad. Sci. U. S. A. 122 (2025) e2507542122. doi: 10.1073/pnas.2507542122
93. [93]
  J. Huo, Y. Wang, L. Liu, et al., Bioact. Mater. 62 (2026) 248–262.
94. [94]
  A. Ribas, J.D. Wolchok, Science 359 (2018) 1350–1355. doi: 10.1126/science.aar4060
95. [95]
  B. Comin-Anduix, H. Escuin-Ordinas, F.J. Ibarrondo, OncoTargets Ther. 9 (2016) 1767–1776.
96. [96]
  R. Jotte, F. Cappuzzo, I. Vynnychenko, et al., J. Thorac. Oncol. 15 (2020) 1351–1360. doi: 10.1016/j.jtho.2020.03.028
97. [97]
  P. Kawczak, I.J. Feszak, T. Bączek, Cancers 17 (2025) 2805. doi: 10.3390/cancers17172805
98. [98]
  X. Han, H. Li, D. Zhou, et al., Acc. Chem. Res. 53 (2020) 2521–2533. doi: 10.1021/acs.accounts.0c00339
99. [99]
  A. Galstyan, J.L. Markman, E.S. Shatalova, et al., Nat. Commun. 10 (2019) 3850. doi: 10.1038/s41467-019-11719-3
100. [100]
  S. Ruan, R. Xie, L. Qin, et al., Nano Lett. 19 (2019) 8318–8332. doi: 10.1021/acs.nanolett.9b03968
101. [101]
  X. Yang, C. Hu, F. Tong, et al., Adv. Funct. Mater. 29 (2019) 1901896. doi: 10.1002/adfm.201901896
102. [102]
  N. Zhang, J. Song, Y. Liu, et al., J. Control. Release 306 (2019) 15–28. doi: 10.1016/j.jconrel.2019.05.036
103. [103]
  C.G. Buss, S.N. Bhatia, Proc. Natl. Acad. Sci. U. S. A. 117 (2020) 13428–13436. doi: 10.1073/pnas.2001569117
104. [104]
  A. Monfaredan, S. Şen, N.K. Fathi, et al., Int. J. Mol. Sci. 26 (2025) 8448. doi: 10.3390/ijms26178448
105. [105]
  Y. Yin, J. Guo, S. Zhang, et al., Chin. Chem. Lett. 36 (2025) 110771. doi: 10.1016/j.cclet.2024.110771
106. [106]
  S. Dadfar, Y. Eivazzadeh, H. Molavi, et al., Inflamm. Res. 75 (2026) 58. doi: 10.1007/s00011-026-02211-y
107. [107]
  J. Wang, C. Klein, J.R. Cochran, et al., Trends Pharmacol. Sci. 46 (2025) 638–652. doi: 10.1016/j.tips.2025.05.008
108. [108]
  Q. Lecocq, M. Keyaerts, N. Devoogdt, et al., Int. J. Mol. Sci. 22 (2020) 75. doi: 10.3390/ijms22010075
109. [109]
  W.J. Wan, G. Huang, Y. Wang, et al., Acta Biomater. 136 (2021) 473–484. doi: 10.1016/j.actbio.2021.09.040
110. [110]
  T.Y. Huang, G.L. Huang, C.Y. Zhang, et al., Front. Chem. 8 (2020) 1. doi: 10.3389/fchem.2020.00001
111. [111]
  C. Hu, X. He, Y. Chen, et al., Adv. Funct. Mater. 31 (2021) 2007149. doi: 10.1002/adfm.202007149
112. [112]
  R. Mancusi, M. Monje, Nature 618 (2023) 467–479. doi: 10.1038/s41586-023-05968-y
113. [113]
  T. Pu, J. Sun, G. Ren, et al., Signal Transduct. Target. Ther. 10 (2025) 176. doi: 10.1038/s41392-025-02241-8
114. [114]
  F.V. Abeele, M. Salzet, Cancer Lett. 634 (2025) 218070. doi: 10.1016/j.canlet.2025.218070
115. [115]
  M. Amit, T. Eichwald, A. Roger, et al., Nat. Rev. Cancer 25 (2025) 573–589. doi: 10.1038/s41568-025-00831-w
116. [116]
  J. Liu, J. Qin, W. Zheng, et al., Nat. Commun. 17 (2026) 6230. doi: 10.1038/s41467-026-72847-1
117. [117]
  Z. Zhang, P. Chen, Y. Zheng, et al., Sci. Adv. 12 (2026) eady1292. doi: 10.1126/sciadv.ady1292
118. [118]
  W. Wang, H. Chen, S. Yin, et al., J. Cancer Res. Clin. Oncol. 149 (2023) 7969–7979. doi: 10.1007/s00432-023-04685-3
119. [119]
  T.H. Kim, S.H. Lim, H. Lee, et al., Exp. Mol. Med. 58 (2026) 366–381. doi: 10.1038/s12276-026-01650-1
120. [120]
  J. Park, J. Cho, Biomol. Ther. 34 (2026) 491–505. doi: 10.4062/biomolther.2026.036
121. [121]
  N. Luo, L. Ma, N. Ma, et al., Int. Immunopharmacol. 140 (2024) 112759. doi: 10.1016/j.intimp.2024.112759
122. [122]
  C. Xu, X. Ji, Y. Zhou, et al., Adv. Mater. 35 (2023) 2211415. doi: 10.1002/adma.202211415
123. [123]
  X. Liu, J. Zhang, S. Zheng, et al., J. Control. Release 370 (2024) 168–181. doi: 10.1016/j.jconrel.2024.04.031
124. [124]
  T. Sanomachi, Y. Katsuya, T. Nakatsura, et al., Cancer 17 (2025) 1945. doi: 10.3390/cancers17121945
125. [125]
  R. Xu, S. Du, J. Zhu, et al., Cancer Lett. 546 (2022) 215840. doi: 10.1016/j.canlet.2022.215840
126. [126]
  Y. Wang, Y. Wang, W. Yuan, et al., Cell 189 (2026) 1680–1700.e48. e48. doi: 10.1016/j.cell.2025.12.050
127. [127]
  V. Anastasopoulou, H. Schreiber, C.E. Lee, et al., Oncoimmunology 14 (2025) 2514041. doi: 10.1080/2162402X.2025.2514041
128. [128]
  Y. Gao, Y. Gao, Y. Fan, et al., Nat. Mach. Intell. 5 (2023) 236–249. doi: 10.1038/s42256-023-00619-3
129. [129]
  D. Su, F. Zhu, H. Shi, et al., Cell. Mol. Immunol. 23 (2026) 686–700. doi: 10.1038/s41423-026-01418-7
130. [130]
  Y. Zhang, Y. Liu, Q. Wang, et al., Front. Immunol. 17 (2026) 1754735. doi: 10.3389/fimmu.2026.1754735
131. [131]
  L. Li, B. Li, Y. Hao, et al., Adv. Sci. 13 (2026) e18455. doi: 10.1002/advs.202518455
132. [132]
  L. Yu, Y. Liu, X. Lin, Cell. Mol. Immunol. 22 (2025) 712–729. doi: 10.1038/s41423-025-01304-8
133. [133]
  M. Hiltensperger, A.M. Krackhardt, Front. Immunol. 14 (2023) 1121030. doi: 10.3389/fimmu.2023.1121030
134. [134]
  H.Q. Wang, R. Fu, Q.W. Man, et al., J. Clin. Med. 12 (2023) 2173. doi: 10.3390/jcm12062173
135. [135]
  L. Wang, L. Zhang, L.C. Dunmall, et al., Cancer Lett. 591 (2024) 216871. doi: 10.1016/j.canlet.2024.216871
136. [136]
  T.L. Hunter, Y. Bao, Y. Zhang, et al., Science 388 (2025) 1311–1317. doi: 10.1126/science.ads8473
137. [137]
  A.X. Chen, K.M. Yap, J.S. Kim, et al., Nature 644 (2025) 241–251. doi: 10.1038/s41586-025-09212-7
138. [138]
  Y. Zhu, C. Chen, J. Chen, et al., Adv. Mater. 38 (2026) e20493. doi: 10.1002/adma.202520493
139. [139]
  P. Yao, Y.G. Liu, G. Huang, et al., Exp. Hematol. Oncol. 13 (2024) 118. doi: 10.1186/s40164-024-00583-7
140. [140]
  F.D. Dos Reis, Y. Saidani, P. Martín-Rubio, et al., Front. Immunol. 16 (2025) 1603757. doi: 10.3389/fimmu.2025.1603757
141. [141]
  B.S. Garrison, H. Deng, G. Yucel, et al., Blood 138 (2021) 2799. doi: 10.1182/blood-2021-154201
142. [142]
  S.Y. Lim, Y. Kim, S. Han, et al., Biomed. Pharmacother. 193 (2025) 118691. doi: 10.1016/j.biopha.2025.118691
143. [143]
  F. Hu, J. Li, Y. Wang, et al., Nat. Biomed. Eng. 10 (2026) 765–784.
144. [144]
  M. Wang, Z. Qin, X.W. Bian, et al., Cancer Commun. 45 (2025) 1344–1366. doi: 10.1002/cac2.70053
145. [145]
  J. Lu, Y. Ma, Q. Li, et al., Biomark. Res. 12 (2024) 86. doi: 10.1186/s40364-024-00637-2
146. [146]
  K.M. Maalej, M. Merhi, V.P. Inchakalody, et al., Mol. Cancer 22 (2023) 20. doi: 10.1186/s12943-023-01723-z
147. [147]
  K.A. Reiss, M.G. Angelos, E.C. Dees, et al., Nat. Med. 31 (2025) 1171–1182. doi: 10.1038/s41591-025-03495-z
148. [148]
  M. Klichinsky, M. Ruella, O. Shestova, et al., Nat. Biotechnol. 38 (2020) 947–953. doi: 10.1038/s41587-020-0462-y
149. [149]
  S. Chen, Y. Wang, J. Dang, et al., Nat. Commun. 16 (2025) 4069. doi: 10.1039/d5ob00425j
150. [150]
  S. Pierini, R. Gabbasov, M.C. Oliveira-Nunes, et al., Nat. Commun. 16 (2025) 706. doi: 10.1038/s41467-024-55770-1
151. [151]
  Y. Zhang, R. Hu, X. Xie, et al., Ann. Hematol. 104 (2025) 4305–4317. doi: 10.1007/s00277-025-06538-0
152. [152]
  R. Zhang, J. Zhang, H. Zhang, et al., Clin. Transl. Med. 15 (2025) e70536. doi: 10.1002/ctm2.70536
153. [153]
  L. Guo, J. Ding, W. Zhou, Chin. Chem. Lett. 35 (2024) 108557. doi: 10.1016/j.cclet.2023.108557
154. [154]
  M. Jayaprakash, D.V. Kumar, G. Chakraborty, et al., Biomed. Pharmacother. 192 (2025) 118559. doi: 10.1016/j.biopha.2025.118559
155. [155]
  M. Sun, J. Yang, L. Li, et al., Chin. Chem. Lett. 36 (2025) 111093. doi: 10.1016/j.cclet.2025.111093
156. [156]
  L. Niu, Z. Deng, Y. Jin, et al., Protein Cell 17 (2026) 279–303. doi: 10.1093/procel/pwaf085
157. [157]
  H. Wang, F. Xu, C. Wang, Semin. Cancer Biol. 112 (2025) 58–70. doi: 10.1016/j.semcancer.2025.03.003
158. [158]
  Z.P. Zou, X.G. Wang, X.R. Shi, et al., Adv. Sci. 12 (2025) e06486. doi: 10.1002/advs.202406486
159. [159]
  V. Staedtke, N. Sun, R. Bai, Semin. Cancer Biol. 100 (2024) 39–48. doi: 10.1016/j.semcancer.2024.03.003
160. [160]
  D.H. Nguyen, A. Chong, Y. Hong, et al., Nat. Commun. 14 (2023) 3553. doi: 10.1038/s41467-023-39224-8
161. [161]
  M.O. Din, T. Danino, A. Prindle, et al., Nature 536 (2016) 81–85. doi: 10.1038/nature18930
162. [162]
  T. Shao, M. Xu, J. Li, et al., Acta Pharm. Sin. B 15 (2025) 1703–1705. doi: 10.1016/j.apsb.2025.01.020
163. [163]
  C.J. Thomas, K. Delgado, K. Sawant, et al., Cancers 16 (2024) 3810. doi: 10.3390/cancers16223810
164. [164]
  S. Liu, Z. Zhong, Q. Tu, et al., Front. Immunol. 16 (2025) 1698158. doi: 10.3389/fimmu.2025.1698158
165. [165]
  Y. Li, X. Qin, C. Liang, et al., Front. Pharmacol. 17 (2026) 1751206. doi: 10.3389/fphar.2026.1751206
166. [166]
  Z. Zhao, Y. Shen, T. Liang, Clin. Transl. Med. 15 (2025) e70503. doi: 10.1002/ctm2.70503
167. [167]
  J. Smestad, J. Rieth, D. Laux, et al., Cells 14 (2025) 1620. doi: 10.3390/cells14201620
168. [168]
  J. Wen, S.J. Li, R. Xiao, X. Shi, Z.J. Sun, et al., Adv. Mater. 38 (2026) e19222. doi: 10.1002/adma.202519222
169. [169]
  W.D. Wang, C.H. Yang, W.T. Mo, et al., ACS Nano 20 (2026) 9784–9801. doi: 10.1021/acsnano.5c19047
170. [170]
  H. Zhang, K. Wen, T. Liu, et al., Biomaterials 332 (2026) 124143. doi: 10.1016/j.biomaterials.2026.124143
171. [171]
  K. Ma, T. Liu, W.B. Huan, et al., Nano Today 67 (2026) 102945. doi: 10.1016/j.nantod.2025.102945
172. [172]
  S. Li, Y. Jin, H. Wu, et al., J. Hematol. Oncol. 19 (2025) 5. doi: 10.1186/s13045-025-01765-4
173. [173]
  X. Huang, F. Wu, J. Ye, et al., Acta Pharm. Sin. B 14 (2024) 2402–2427. doi: 10.1016/j.apsb.2024.01.010
174. [174]
  F. Liu, Y. Zhang, Y. Xu, et al., Bioorg. Chem. 179 (2026) 110045. doi: 10.1016/j.bioorg.2026.110045
175. [175]
  Z. Feng, S. Zhou, X. Li, et al., Chin. Chem. Lett. 37 (2026) 112338. doi: 10.1016/j.cclet.2025.112338
176. [176]
  P. Liu, Q. Chen, J. Li, Bioorg. Chem. 180 (2026) 110042. doi: 10.1016/j.bioorg.2026.110042
177. [177]
  N. Wu, Z. Xu, S. Dai, et al., Front. Pharmacol. 17 (2026) 1815569. doi: 10.3389/fphar.2026.1815569
178. [178]
  K. Li, G. Dong, S. Wu, et al., Chin. Chem. Lett. 36 (2025) 110280. doi: 10.1016/j.cclet.2024.110280
179. [179]
  F. Tong, Y. Wang, Y. Xu, et al., Nat. Commun. 15 (2024) 10382. doi: 10.1038/s41467-024-54854-2
180. [180]
  F. Xue, M. Zhang, S. Li, et al., Nat. Commun. 16 (2025) 5514. doi: 10.1038/s41467-025-61272-5
181. [181]
  Q. Hu, Y. Cao, P. Ren, et al., Proc. Natl. Acad. Sci. U. S. A. 123 (2026) e2518248123. doi: 10.1073/pnas.2518248123
182. [182]
  A. Pandey, A.K. Chettupalli, S.P.N. Bukke, et al., Int. Immunopharmacol. 167 (2025) 115694. doi: 10.1016/j.intimp.2025.115694
183. [183]
  O. Eladl, Biochem. Pharmacol. 242 (2025) 117297. doi: 10.1016/j.bcp.2025.117297
184. [184]
  V. Oleinikovas, P. Gainza, T. Ryckmans, et al., Annu. Rev. Pharmacol. Toxicol. 64 (2024) 291–312. doi: 10.1146/annurev-pharmtox-022123-104147
185. [185]
  K. Baek, R. Metivier, S. Roy Burman, et al., Nat. Commun. 16 (2025) 6831. doi: 10.1038/s41467-025-62099-w
186. [186]
  J.J. Driscoll, J.J. Ignatz-Hoover, J. Immunother. Cancer 13 (2025) 1162.
187. [187]
  S.M. Banik, K. Pedram, S. Wisnovsky, et al., Nature 584 (2020) 291–297. doi: 10.1038/s41586-020-2545-9
188. [188]
  B. Li, Y. Li, J. Zhang, et al., Cell Chem. Biol. 33 (2026) 433–460. doi: 10.1016/j.chembiol.2026.01.008
189. [189]
  W. Zhang, J. Jiang, Y. Sun, et al., J. Transl. Med. 24 (2026) 660. doi: 10.1145/3801228.3801330
190. [190]
  Y. Jiang, G. Ahn, M. Rahman, et al., Cancer Res. 84 (2024) 3880. doi: 10.1158/1538-7445.am2024-3880
191. [191]
  T. Peng, M. Su, Z. Zhang, et al., JACS Au 6 (2026) 144–153. doi: 10.1021/jacsau.5c00978
192. [192]
  Y. Xiao, X. Zhou, X. Niu, et al., J. Chem. Soc. 148 (2026) 7008–7023. doi: 10.1021/jacs.5c17801
193. [193]
  D. Takahashi, H. Arimoto, Cell Chem. Biol. 28 (2021) 1061–1071. doi: 10.1016/j.chembiol.2021.05.006
194. [194]
  Y. Zhang, X. Liu, D.J. Klionsky, et al., Life Med. 1 (2022) 120–148. doi: 10.1093/lifemedi/lnac043
195. [195]
  Y. Wang, L. Yang, C. Yan, et al., Sci. Adv. 10 (2024) eadn8079. doi: 10.1126/sciadv.adn8079
196. [196]
  Z. Song, Y. Gao, X. Zou, et al., J. Control. Release 389 (2026) 114450. doi: 10.1016/j.jconrel.2025.114450
197. [197]
  M. Liu, Z. Liu, G. Qin, et al., Nano Lett. 23 (2023) 4965–4973. doi: 10.1021/acs.nanolett.3c00798
198. [198]
  K. Watanabe, H. Nishikawa, Pathol. Int. 76 (2026) e70117. doi: 10.1111/pin.70117
199. [199]
  M. Liu, C. Li, L.T. Feng, et al., J. Immunother. Cancer 13 (2025) e011783. doi: 10.1136/jitc-2025-011783
200. [200]
  T. Zhou, J. Yang, Y. Tan, et al., Chaos Soliton. Fract. 197 (2025) 116418. doi: 10.1016/j.chaos.2025.116418
201. [201]
  O. Liseth, E. Appleton, B. Kendall, et al., Sci. Adv. 12 (2026) eaef5331. doi: 10.1126/sciadv.aef5331
202. [202]
  S.N. Mirbahari, M. Bakhtiyaridovvombaygi, H. Mahdizadeh, et al., J. Clin. Pharm. Ther. 2025 (2025) 6036890. doi: 10.1155/jcpt/6036890
203. [203]
  L.Y. Su, Y. Tian, Q. Zheng, et al., Cell Chem. Biol. 31 (2024) 1219–1230.e5. doi: 10.1016/j.chembiol.2024.01.002
1. [1]
  Shao-Qi Guan , Chen-Hui Liu , Ya-Ping Wang , Xiao-Dong Zhang , Zhong-Min Cao , Mei Pan . Cancer cell membrane-biomimetic metallacycles for tumor microenvironment-responsive ferroptosis/apoptosis therapy with low systemic toxicity. Chinese Chemical Letters, 2026, 37(7): 111692-. doi: 10.1016/j.cclet.2025.111692
2. [2]
  Ping Sun , Nansha Gao , Li Yang , Yao Yang , Li Huang , Hongzhong Chen , Hualin Ma , Xiaowei Zeng . Dissolved microneedle loading polydopamine nanoparticles induced tumor-associated macrophage polarization and promoted dendritic cell maturation for tumor immunotherapy. Chinese Chemical Letters, 2026, 37(9): 112071-. doi: 10.1016/j.cclet.2025.112071
3. [3]
  Xiaopeng Han , Jiayin Li , Fei Li , Zhongyue Yuan , Hao Li , Lei Yang , Yan-Ming Xia , Chao Teng , Chao Qin , Lifang Yin . ROS-sensitive dihydroartemisinin prodrug amplify chemo-immunotherapy efficacy of doxorubicin by coordinating robust tumor cell immunogenic cell death and PD-L1 blockade. Chinese Chemical Letters, 2026, 37(2): 111335-. doi: 10.1016/j.cclet.2025.111335
4. [4]
  Fengyun Li , Zerong Pei , Shuting Chen , Gen li , Mengyang Liu , Liqin Ding , Jingbo Liu , Feng Qiu . Multifunctional nano-herb based on tumor microenvironment for enhanced tumor therapy of gambogic acid. Chinese Chemical Letters, 2024, 35(5): 108752-. doi: 10.1016/j.cclet.2023.108752
5. [5]
  Zhiyuan Huang , Fangqiu Fu , Chaoqiang Deng , Shiyang Wu , Mingxuan Huang , Xianyi Sha , Ming Q Wei , Zhiwen Zhang , Yang Zhang . Strategies of designing lymph nodes-targeting nanoparticles for cancer immunotherapy. Chinese Chemical Letters, 2026, 37(9): 111993-. doi: 10.1016/j.cclet.2025.111993
6. [6]
  Guanghui Lin , Jieyao Chen , Xiaojia Liu , Yitong Lin , Xudong Zhu , Guotao Yuan , Bowen Yang , Shuanshuan Guo , Yue Pan , Jianhua Zhou . Sustained modulation of tumor microenvironment via sorafenib-loaded mesoporous ferromanganese nanozymes for enhanced apoptosis-ferroptosis cancer therapy. Chinese Chemical Letters, 2025, 36(8): 111018-. doi: 10.1016/j.cclet.2025.111018
7. [7]
  Xinyu Wang , Yunquan Yang , Shaojing Zhao , Yuanyu Tang , E Pang , Wenjie Gao , Jiwei Li , Qingxu Diao , Lianhong Zou , Jie Zeng , Minhuan Lan , Jianing Yi . Synergistic antitumor therapy via immunophototherapy induced multi-modal cell death and immune microenvironment reprogramming. Chinese Chemical Letters, 2026, 37(10): 112129-. doi: 10.1016/j.cclet.2025.112129
8. [8]
  Yanjun Cai , Yong Jiang , Yu Chen , Erzhuo Cheng , Yuan Gu , Yuwei Li , Qianqian Liu , Jian Zhang , Jifang Liu , Shisong Han , Bin Yang . Amplifying STING activation and immunogenic cell death by metal-polyphenol coordinated nanomedicines for enhanced cancer immunotherapy. Chinese Chemical Letters, 2025, 36(5): 110437-. doi: 10.1016/j.cclet.2024.110437
9. [9]
  Kun-Heng Li , Hong-Yang Zhao , Dan-Dan Wang , Ming-Hui Qi , Zi-Jian Xu , Jia-Mi Li , Zhi-Li Zhang , Shi-Wen Huang . Mitochondria-targeted nano-AIEgens as a powerful inducer for evoking immunogenic cell death. Chinese Chemical Letters, 2024, 35(5): 108882-. doi: 10.1016/j.cclet.2023.108882
10. [10]
  Ning Tian , Haoyu Ju , Qian Hu , Qifeng Hou , Yiping Lu , Yu Liu , Jinmei Huang , Zhong-Hong Zhu , Bin Zhang , Jin Huang , Ming-Hua Zeng . Solvothermal domino synthesis of an ER-targeted iron(Ⅱ) complex for inducing immunogenic cell death. Chinese Chemical Letters, 2026, 37(6): 111038-. doi: 10.1016/j.cclet.2025.111038
11. [11]
  Li Fu , Ziye Su , Shuyang Wu , Yanfen Cheng , Chuan Hu , Jinming Zhang . Redox-responsive hyaluronic acid-celastrol prodrug micelles with glycyrrhetinic acid co-delivery for tumor combination therapy. Chinese Chemical Letters, 2025, 36(5): 110227-. doi: 10.1016/j.cclet.2024.110227
12. [12]
  Xin Li , Fei Xiong , Xudong Cao , Wei Liu , Haobo Chen , Jiayu He , Weina Zhang , Longguang Tang , Wei Huang , Xikuang Yao . CD44-targeting and ZIF-8 gated gold nanocage for programmed breast cancer therapy through Pt-induced immunogenic cell death. Chinese Chemical Letters, 2026, 37(1): 110970-. doi: 10.1016/j.cclet.2025.110970
13. [13]
  Xueying Shi , Xiaoxuan Zhou , Bing Xiao , Hongxia Xu , Wei Zhang , Hongjie Hu , Shiqun Shao , Zhuxian Zhou , Youqing Shen , Xiaodan Xu , Jianbin Tang . A β-lapachone-loaded iron-polyphenol nanocomplex enhances chemodynamic therapy through cascade amplification of ROS in tumor. Chinese Chemical Letters, 2025, 36(5): 110178-. doi: 10.1016/j.cclet.2024.110178
14. [14]
  Zhiqiang Cui , Dongxiang Zhang , Yanru Huang , Chunyu Shao , Yiming Zhang , Changliang Sun , Xin-Dong Jiang , Xiaohong Sun , Qinghuan Xiao . Novel 1-phenylethyl-containing aza-BDOIPY for phototherapy and simultaneous monitoring of tumor immune microenvironment reprogramming. Chinese Chemical Letters, 2025, 36(7): 110460-. doi: 10.1016/j.cclet.2024.110460
15. [15]
  Xiaoxuan Zhou , Qiuhui Hu , Chengbin He , Yue Qian , Xiaodan Xu , Jianbin Tang , Hongjie Hu . Ferrocene-integrated hypericin self-assembly nanocomplex directs ferroptosis for enhanced cascade tumor photodynamic therapy and immune effects. Chinese Chemical Letters, 2026, 37(7): 111645-. doi: 10.1016/j.cclet.2025.111645
16. [16]
  Kaiyue Yang , Yifan Zhang , Shamei Luo , Chenxi Yu , Lin Chen , Qingyu Yu , Chenlu Huang , Guilei Ma , Linhua Zhang , Dunwan Zhu . Multifunctional nanoadjuvants-aided synergistic photothermal-immunotherapy of tumor. Chinese Chemical Letters, 2026, 37(4): 112324-. doi: 10.1016/j.cclet.2025.112324
17. [17]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
18. [18]
  Xiu Pan , Kai-Hui Yan , Meng-Die Wang , Ling-Xiao Zhou , Kun-Mei Liu , Jin-Yu An , Yan Jiang , Shun Feng , Ming-Yu Wu . Boosting tumor retention via water solubility and molecular charge engineering for enhanced photoimmunotherapy. Chinese Chemical Letters, 2026, 37(12): 112291-. doi: 10.1016/j.cclet.2025.112291
19. [19]
  Shi-Hao Wang , Qiu-Yi Duan , Rufeng Zhang , Zihao Wang , Zi-Xi Wang , Yang Shen , Fu-Gen Wu . A liquid PEG depot capable of triggering intratumoral O₂/H₂O₂ generation and neutralization/calcification for realizing light irradiation-free photodynamic therapy and immunotherapy. Chinese Chemical Letters, 2026, 37(8): 111772-. doi: 10.1016/j.cclet.2025.111772
20. [20]
  Meng Pan , Dong Mo , Wen Chen , Yun Yang , Qingya Liu , Yujia Wei , Xicheng Li , Hanzhi Deng , Yan Yu , Liping Yuan , Yu Liu , Zhiyong Qian . Ultrasound-augmented chemodynamic and chemotherapy amplify cascade oxidative stress for potentiating immunogenic cell death in pancreatic cancer treatment. Chinese Chemical Letters, 2026, 37(9): 112846-. doi: 10.1016/j.cclet.2026.112846

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(21)
HTML views(0)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142